Vaishali Pharma Ltd
Pharmaceuticals & Biotechnology | Small Cap
Vaishali Pharma Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and growth, driven by effective management of debt and significant increases in revenue and net income. Profitability is also a notable strength, supported by healthy gross profit and operating margins. However, the company faces challenges in liquidity, particularly with low cash and operating cash flow ratios. Efficiency metrics are varied, with strong asset and inventory turnover balanced by slow receivables turnover. Overall, the company shows potential for continued growth, but needs to address its liquidity and efficiency in certain areas to ensure long-term financial stability.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio8.80
- Financial Ratio4.00
- Profitability Ratio9.20
- Efficiency Ratio6.00
- Coverage Ratio4.40
- Solvency Ratio10.00
- Liquidity Ratio6.22
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Vaishali Pharma Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and growth, driven by effective management of debt and significant increases in revenue and net income. Profitability is also a notable strength, supported by healthy gross profit and operating margins. However, the company faces challenges in liquidity, particularly with low cash and operating cash flow ratios. Efficiency metrics are varied, with strong asset and inventory turnover balanced by slow receivables turnover. Overall, the company shows potential for continued growth, but needs to address its liquidity and efficiency in certain areas to ensure long-term financial stability.
Overall Valuation Score
P/E RATIO (TTM)
276.33
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
103.62
P/B RATIO
1.32
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
0.90
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
1.10
EV/EBITDA RATIO
29.57
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹8.29 as on Jun 15, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company demonstrates strong growth in several key areas, including revenue, EPS, asset, and net income. However, the negative operating profit growth rate raises concerns about the sustainability of this growth. The weighted average calculation, emphasizing recent performance, suggests that while the company is expanding, operational efficiency and profitability need attention to ensure balanced and sustainable growth.
| Growth Ratios | Mar 2026 |
|---|---|
| Revenue Growth Rate | |
| Operating Profit Growth Rate | |
| Earnings Per Share (EPS) Growth | |
| Asset Growth Rate | |
| Net Income Growth Rate |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios reveal strengths in capital expenditure management but weaknesses in earnings per share and book value per share. The low adjusted and cash EPS, coupled with a low book value per share, suggest challenges in generating shareholder value. However, strong capital expenditures may indicate reinvestment in the company's future growth. The weighted average calculation, emphasizing recent data, highlights the need to improve earnings and book value to enhance overall financial performance.
| Financial Ratios | Mar 2026 |
|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 0.31 |
| Cash Earnings Per Share (Cash EPS) | 0.38 |
| Book Value Per Share | 5.31 |
| Dividend Per Share (DPS) | 0 |
| Capital Expenditures (CapEx) |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates strong profitability, as reflected by high gross profit margin, ROCE, ROE, and operating margin. However, a low ROA suggests that the company's asset utilization could be improved. The weighted average calculation, emphasizing recent performance, underscores the company's ability to generate profits from its capital and equity, but also highlights the need to enhance asset efficiency.
| Profitability Ratios | Mar 2026 |
|---|---|
| Gross Profit Margin | 2.75 |
| Return on Capital Employed (ROCE) | 9.33 |
| Return on Equity (ROE) | 5.8 |
| Return on Assets (ROA) | 3.25 |
| Operating Margin | 3.67 |
| Net Margin | 3.67 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency in asset utilization presents a mixed view. While fixed asset and inventory turnover are robust, indicating effective use of these assets, the low receivables and capital turnover ratios suggest challenges in managing receivables and overall capital deployment. The high receivable days further underscores the difficulty in collecting payments promptly. The weighted average calculation, emphasizing recent data, highlights the need for improvements in these specific areas to enhance overall operational efficiency.
| Efficiency Ratios | Mar 2026 |
|---|---|
| Fixed Asset Turnover Ratio | 54.5 |
| Inventory Turnover Ratio | 35.33 |
| Receivables Turnover Ratio | 2.15 |
| Days Sales in Inventory Ratio | 10.33 |
| Receivable Days | 170 |
| Capital Turnover Ratio | 1.45 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios indicate a moderate ability to meet its interest obligations, but a lack of dividend coverage. While the interest coverage ratio is adequate, the absence of equity dividend coverage suggests that the company is not distributing dividends to shareholders. The weighted average calculation, emphasizing recent performance, underscores the need to improve both interest and dividend coverage to enhance financial stability and shareholder returns.
| Coverage Ratios | Mar 2026 |
|---|---|
| Interest Coverage Ratio | 3.5 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits excellent solvency, reflecting a strong financial structure with low debt levels relative to equity and assets. This indicates a reduced risk of financial distress and a greater capacity to absorb financial shocks. The weighted average calculation, focusing on recent performance, highlights a consistent trend of maintaining a conservative capital structure, which is a positive indicator for long-term financial health.
| Solvency Ratios | Mar 2026 |
|---|---|
| Debt Ratio | 0.08 |
| Debt to Equity Ratio | 0.09 |
| Equity Ratio | 0.92 |
| Debt To Asset Ratio | 0.05 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position presents a mixed picture. While the current and quick ratios suggest a good ability to meet short-term obligations, the low cash ratio indicates a reliance on current assets other than cash. The negative operating cash flow ratio is a concern, suggesting potential difficulties in generating cash from core operations. The weighted average calculation, emphasizing recent performance, underscores the need for improved cash management.
| Liquidity Ratios | Mar 2026 |
|---|---|
| Current Ratio | 2.42 |
| Quick Ratio | 2.36 |
| Cash Ratio | 0.02 |
| Operating Cash Flow Ratio | 0 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 8.88 | Undervalued | 17.00 | 10.65 | 13.00 |
| 2 | Vaishali Pharma Ltd | 6.74 | 103.62 | Overvalued | 4.00 | 0.31 | 4.00 |
| 3 | Mono Pharmacare Ltd | 6.16 | 6.26 | Neutral | 8.00 | 1.75 | 3.00 |
| 4 | JFL Life Sciences Ltd | 6.07 | 9.43 | Neutral | 12.00 | 1.94 | 6.00 |
| 5 | Walpar Nutritions Ltd | 5.29 | 9.26 | Neutral | 6.66 | 2.09 | 3.00 |
| 6 | Quest Laboratories Ltd | 5.27 | 11.21 | Neutral | 18.00 | 9.16 | 15.00 |
| 7 | Sotac Pharmaceuticals Ltd | 5.27 | 21.26 | Neutral | 18.00 | 4.45 | 6.00 |
| 8 | Zenith Drugs Ltd | 4.63 | 7.52 | Neutral | 17.00 | 2.30 | 10.00 |
| 9 | Mangalam Drugs and Organics Ltd | 4.50 | -1.07 | Neutral | -15.00 | -27.68 | -44.00 |
| 10 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 11 | Krebs Biochemicals & Industries Ltd | 4.16 | -5.27 | Highly Undervalued | -4.00 | -12.49 | -4.00 |
The management effectiveness of Vaishali Pharma Ltd is a mix of strengths and weaknesses. While the company shows positive TTM sales growth, this is contrasted by a high P/E ratio and negative OPM. The relatively low promoter holding and high public holding also introduce concerns. These factors suggest a need to evaluate the company's strategic direction and operational efficiency.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | TTM Sales Growth | 15% | Revenue expansion indicates market traction |
| CONS | PE Ratio | 170 | Significantly higher than peers |
| Promoter Holding | 26.32% | Relatively low, potentially indicating less alignment with shareholder interests | |
| OPM | -18.73% | Negative OPM indicates operational inefficiency |
Financial Performance & Growth
Vaishali Pharma exhibits mixed financial performance. While sales have grown, profitability has declined. Compounded Sales Growth shows positive trends over the years, but Compounded Profit Growth shows decline. The negative OPM in the latest quarters raises concerns about operational efficiency.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Compounded Sales Growth (%) | 8.7% | 19.8% | -8.12% | 23.86% | 14.78% |
| Compounded Profit Growth (%) | 0.73% | 7.48% | 6.6% | 0.72% | 0.82 |
Capital Efficiency & Returns
Capital efficiency and returns for Vaishali Pharma are weak. ROCE is low compared to its peers. The ROE is also relatively low, indicating that shareholder funds are not generating strong returns. This suggests the company needs to improve its asset utilization and profitability to enhance returns on capital and equity.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | ROCE (%) | 15.27% | 12.9% | 11.95% | 21.69% | 5.72% | 4.19% | | ROE (%) | N/A | N/A | N/A | N/A | N/A | 2.09% |
Financial Health & Prudence
Vaishali Pharma's financial health presents a mixed outlook. The debt levels appear to be manageable, with a decrease in borrowings over the years. However, the interest coverage ratio should be monitored to ensure the company can comfortably meet its interest obligations. The company does not pay dividends which may not be appealing to investors seeking regular income.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Borrowings (Rs. Cr.) | 21.63 | 19.44 | 18.24 | 14.73 | 13.49 | 12.32 | | Dividend Payout (%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00%|
Strategic & Operational Indicators
Vaishali Pharma's strategic and operational indicators reveal some inefficiencies. Debtor days are high, indicating a longer time to collect receivables, while inventory days are volatile. The cash conversion cycle is also extended, suggesting working capital management could be improved to enhance operational efficiency.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Debtor Days | 156.43 | 231.39 | 322.1 | 280.9 | 209.11 | 172.20 | | Inventory Days | 19.7 | 8.09 | 4.99 | 20.36 | 1.86 | 20.49 | | Cash Conversion Cycle | 79.71 | 117.17 | 127.44 | 181.11 | 115.87 | 77.06 |
Vaishali Pharma's risk profile is moderate. The company faces risks from segment performance volatility, as evidenced by fluctuations in quarterly sales and profit growth. Additionally, high debtor days and an extended cash conversion cycle point to working capital management issues that could strain liquidity. While the company's debt levels are manageable, these operational and financial factors suggest a need for careful monitoring.
Segment performance volatility
Segment performance volatility is evident in Vaishali Pharma's quarterly results. There are fluctuations in both sales and profit growth, indicating inconsistent performance across different periods. The quarterly sales and profit growth rates vary significantly, suggesting potential challenges in maintaining stable performance across all segments.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YOY Sales Growth (%) | 34.59 | 23.10 | -33.74 | -9.83 | 3.27 | 31.83 | -4.48 | 38.88 | 23.48 | 34.72 | 65.39 | 0.04 | -0.46 |
| YOY Profit Growth (%) | 113.79 | 86.42 | 42.14 | 65.22 | 120.00 | 5.30 | -14.57 | -20.68 | -1163.64 | 6.92 | 15.88 | -31.75 | 8.33 |
Regulatory compliance cost trends
The provided data does not offer specific figures on regulatory compliance costs. The expenses data does not specifically break out regulatory costs, it is difficult to assess this risk.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe